These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 17414500)

  • 1. Stability and compatibility of histamine H2-receptor antagonists in parenteral nutrition mixtures.
    Puzovic M; Hardy G
    Curr Opin Clin Nutr Metab Care; 2007 May; 10(3):311-7. PubMed ID: 17414500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicochemical stability of parenteral nutrition supplied as all-in-one for neonates.
    Skouroliakou M; Matthaiou C; Chiou A; Panagiotakos D; Gounaris A; Nunn T; Andrikopoulos N
    JPEN J Parenter Enteral Nutr; 2008; 32(2):201-9. PubMed ID: 18407915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term stability of cimetidine in total parenteral nutrition.
    Allwood MC; Martin HJ
    J Clin Pharm Ther; 1996 Feb; 21(1):19-21. PubMed ID: 8737179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physicochemical stability and compatibility testing of levetiracetam in all-in-one parenteral nutrition admixtures in daily practice.
    Aeberhard C; Steuer C; Saxer C; Huber A; Stanga Z; Mühlebach S
    Eur J Pharm Sci; 2017 Jan; 96():449-455. PubMed ID: 27742594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histamine receptor antagonists and lipid stability in total nutrient admixtures.
    Hatton J; Luer M; Hirsch J; Westrich T; Holstad S
    JPEN J Parenter Enteral Nutr; 1994; 18(4):308-12. PubMed ID: 7933436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance and assessment of the compatibility of mixed solutions with fat emulsion components for parenteral nutrition].
    Semler P; Sommermeyer K
    Infusionsther Klin Ernahr; 1987 Dec; 14(6):274-82. PubMed ID: 3126138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ergonomic and economic aspects of total parenteral nutrition.
    Genton L; Mühlebach S; Dupertuis YM; Pichard C
    Curr Opin Clin Nutr Metab Care; 2006 Mar; 9(2):149-54. PubMed ID: 16477180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dilute iron dextran formulation for addition to parenteral nutrient solutions.
    Kwong KW; Tsallas G
    Am J Hosp Pharm; 1980 Feb; 37(2):206-10. PubMed ID: 6767401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments in aluminium contamination of products used in parenteral nutrition.
    Gura KM; Puder M
    Curr Opin Clin Nutr Metab Care; 2006 May; 9(3):239-46. PubMed ID: 16607123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of doripenem in vitro in representative infusion solutions and infusion bags.
    Psathas PA; Kuzmission A; Ikeda K; Yasuo S
    Clin Ther; 2008 Nov; 30(11):2075-87. PubMed ID: 19108795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compatibility and stability of 5-HT3 receptor antagonists: a pharmacology review.
    Longfield V
    Oncol Nurs Forum; 2002; 29(10):1469-82. PubMed ID: 12432417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug stability and compatibility in oncology care.
    Williams DA
    J Infus Chemother; 1996; 6(4):195-202. PubMed ID: 9229315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous histamine H2-receptor antagonists and parenteral nutrition: patterns of use.
    Bone BM; Maksym CJ; Kirking DM; Georgal BA; Jarvis CL; Dunn-Kucharski VA; Berardi RR
    Am J Health Syst Pharm; 1995 May; 52(10):1082-6. PubMed ID: 7656098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of histamine (H2)-receptor antagonists in total parenteral nutrition patients.
    Baptista RJ
    Am J Med; 1987 Dec; 83(6A):53-7. PubMed ID: 2892408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenteral nutrient admixtures as drug vehicles: theory and practice in the critical care setting.
    Driscoll DF; Baptista RJ; Mitrano FP; Mascioli EA; Blackburn GL; Bistrian BR
    DICP; 1991 Mar; 25(3):276-83. PubMed ID: 1674183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finding new solutions in pediatric parenteral admixtures: how to improve quality and to deal with shortages.
    Watrobska-Swietlikowska D; Kwidzynska A; Szlagatys-Sidorkiewicz A; Sznitowska M; Klek S
    Nutr Hosp; 2014 Jul; 30(1):84-93. PubMed ID: 25137266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of famotidine in commonly used nutritional infusion fluids.
    Underberg WJ; Koomen JM; Beijnen JH
    J Parenter Sci Technol; 1988; 42(3):94-7. PubMed ID: 2905734
    [No Abstract]   [Full Text] [Related]  

  • 18. Container effects on the physicochemical properties of parenteral lipid emulsions.
    Gonyon T; Carter PW; Dahlem O; Denet AR; Owen H; Trouilly JL
    Nutrition; 2008; 24(11-12):1182-8. PubMed ID: 18707847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro interactions of captopril with H2-receptor antagonists.
    Sultana N; Arayne MS; Quraish R
    Pak J Pharm Sci; 2007 Apr; 20(2):132-9. PubMed ID: 17416569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of temperature and handling conditions on lipid emulsion stability in veterinary parenteral nutrition admixtures during simulated intravenous administration.
    Thomovsky EJ; Backus RC; Mann FA; Richmond CK; Wagner-Mann CC
    Am J Vet Res; 2008 May; 69(5):652-8. PubMed ID: 18447797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.